Laurus Labs Share Price Analyzed
Laurus Labs’ stock price jumped to a new high of ₹1,043 on Friday, driven by strong earnings expectations. This surpasses its previous high of ₹1,040 set on December 1, 2025. Over the calendar year 2025, the stock has outperformed the market, increasing by 73%, while the BSE Sensex rose by only 8%.
Key Points
- Strong Q2FY26 Earnings: Revenue at ₹1,653 crore, up 35%, EBITDA at ₹429 crore (136% growth).
- Healthy Margins: EBITDA margins remained strong at 26%, driven by operational efficiency.
- CDMO Growth: Sales up 88% for H1FY26, boosted by new deliveries and assets.
- Diverse Client Base: Strong demand from large and small biotech companies.
- Leadership in APIs & FDFs: Focus on key therapeutic areas like anti-retroviral and oncology.
- Positive Outlook: Analysts recommend a ‘BUY’ with a target price of ₹1,075.
The company’s excellent performance stems from a robust September 2025 quarter (Q2FY26) result, showing a substantial revenue increase of 35% and an impressive 136% growth in EBITDA. This highlights the company’s strategic focus on cost management and operational efficiency.
Laurus Labs’ growth is particularly notable in its Contract Development and Manufacturing Organization (CDMO) business. Sales in this segment jumped 88% for the first half of the fiscal year 2025-26, fueled by the delivery of new projects and increased sales from recently operational manufacturing facilities. The company now benefits directly from its prior ₹3,400 crore investment in this area.
The company’s diverse client base, including large pharmaceutical companies and smaller biotechnology firms, is another key factor contributing to its success. This broad reach allows for a steady stream of projects and revenue opportunities, further bolstering its growth prospects. The CDMO division now accounts for 28% of the company’s revenue, up from 16% previously, which has led to significant margin improvements.
Looking ahead, Laurus Labs management has reaffirmed its annual capital expenditure guidance of ₹1,000 crore. Analysts at ICICI Securities continue to monitor key growth drivers, anticipating a shift in the business mix towards the CDMO segment over time.
Ultimately, Laurus Labs’ strong financial performance and strategic investments position it for sustained growth and market leadership.
“`
